ClinicalTrials.gg
CompletedNCT02091310Updated Mar 10, 2015

Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

A Phase 1 interventional study of Placebo and GFT505 in Healthy Volunteers, sponsored by Genfit. Completed at 1 site in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-10.

Sponsored by Genfit · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

In accordance with International Conference on Harmonisation (ICH) E14 guidelines, this Phase I thorough QT (TQT) study will assess the arrhythmogenic potential of GFT505, by evaluating its effect on QT/QTc prolongation in healthy male and female subjects. According to the guidelines, such studies should typically be performed at the expected therapeutic dose and a supra-therapeutic dose that is 3-4-fold higher than the therapeutic dose.

GFT505 has previously been tested at 240 mg/d in 14-day multiple administration to healthy overweight subjects (study GFT505-111-7), and both safety and tolerability were very good. However, this dose corresponds to only 2-fold the expected therapeutic dose of 120 mg/d. Therefore, the current TQT study will be preceded by a multiple ascending dose study in which the safety and tolerability of 2 dose levels of GFT505 (300 and 360 mg) corresponding to 2.5 and 3 times the expected therapeutic dose will be evaluated. The highest dose level for which safety and tolerability are considered satisfactory will be the supra-therapeutic dose used in the TQT study.

Read the detailed description

The present trial is split into two successive parts:

  • Study Part I is a double-blind, randomized, placebo-controlled study designed to obtain safety, tolerability and pharmacokinetic (PK) data after 14-day multiple oral administrations of once-daily increasing doses of GFT505 (300 and 360 mg) in healthy male subjects. The starting dose of 300 mg/day has been selected on the basis of the results of previous clinical trials and corresponds to the highest dose given in healthy subjects according to a single dose regimen (study GFT505-111-7). A total of 24 male subjects will be included, 12 for each cohort (a cohort corresponding to a dose level). In each cohort, 9 subjects will receive GFT505 and 3 will receive placebo. A Safety Review Committee (SRC) will have a formal meeting after full completion of at least 10 out of 12 subjects of each dose level to review under blinded conditions all safety data and to conclude on the safety and tolerability of a given dose level. Between the first and the second dose level, the SRC will give its agreement on the dose escalation, and at completion of the second level the SRC will define the supra-therapeutic dose to be administered in Study Part II.
  • Study Part II will be a parallel group, randomized, placebo-controlled study, with stratification by gender. The study is designed to investigate the potential impact of 14-day multiple oral administrations of once-daily GFT505 on QT/QTc prolongation under conditions of maximal GFT505 exposure, i.e. by administering the expected therapeutic dose of 120 mg/d and a supra-therapeutic dose (defined according to the results of Study Part I), to healthy male and female subjects. A single oral dose of 400 mg moxifloxacin will be used as a positive control in order to document the sensitivity of the experimental conditions. The study treatment administration will be double-blind for placebo and GFT505 and open for moxifloxacin. The ECG readings will be performed under blinded conditions. A preliminary sample size of 128 subjects to have at least 124 evaluable subjects has been fixed by formal justification on a theoretical basis. ECG data collected during Study Part I will support a formal determination using observed data and thus will lead to a final sample size. In all cases, it is anticipated that the sample size could not be less than 124 evaluable subjects. Each gender will represent at least 40% of the study population. Both sub-groups will be balanced between the 4 treatment groups.
02

Conditions studied

  • Healthy Volunteers

Keywords

  • GFT505
  • TQT
  • QT/QTc
  • Pharmacokinetic
  • Healthy subjects
  • Moxifloxacin
03

In context

Lead sponsor

Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part I:

  • Healthy males aged 18 to 45 years inclusive
  • (BMI) ≥ 18 ≤ 30 kg/m²
  • No abnormalities in blood pressure (BP) or heart rate (HR)
  • No clinically relevant abnormalities in 12-lead results

Part II:

  • Healthy males and females aged 18 to 45 years inclusive
  • For female subjects of , use of double method
  • Body Mass Index (BMI) ≥ 18 ≤ 30 kg/m²
  • No clinically relevant abnormalities in blood pressure (BP) or heart rate (HR)
  • No clinically relevant abnormalities in 12-lead ECG results

Exclusion criteria

Exclusion Criteria:

Part I:

  • Evidence of cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric diseases
  • A history of risk factors for "Torsades de Pointe" (e.g., heart failure, hypokalemia, family history of Long Syndrome)
  • Any condition requiring regular concomitant medication, including herbal products and over-the-counter (OTC) medication or predicted need of any concomitant medication during the study
  • Current drug or alcohol abuse [including regular alcohol drinking of more than 21 units per week (1 unit = 4 cL spirits or equivalent)] or a history of drug or alcohol abuse within 1 year before screening
  • Current use of nicotine containing products, i.e., more than 5 cigarettes or equivalent/day and the inability to stop using nicotine containing products during confinement in the clinical center
  • Use of caffeine containing beverages exceeding 500 mg caffeine/day (5 cups of coffee) and the inability to refrain from the use of caffeine containing beverages during confinement in the clinical center
  • Blood donation or loss of significant amount of blood within 2 months prior to the first dosing
  • Any other condition that in the opinion of the Investigator would interfere with the evaluation of the results or constitute a health risk for the subject.

Part II:

  • Evidence of clinically relevant cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric diseases
  • A history of risk factors for "Torsades de Pointe" (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • The use of concomitant medications that prolong the QT/QTc interval
  • Any condition requiring regular concomitant medication, including herbal products and over-the-counter (OTC) medication or predicted need of any concomitant medication during the study
  • Current drug or alcohol abuse [including regular alcohol drinking of more than 21 units (for male) or 14 units (for female) (1 unit = 4 cL spirits or equivalent)] or a history of drug or alcohol abuse within 1 year before screening
  • Current use of nicotine containing products, i.e., more than 5 cigarettes or equivalent/day and the inability to stop using nicotine containing products during confinement in the clinical center
  • Use of caffeine containing beverages exceeding 500 mg caffeine/day (5 cups of coffee) and the inability to refrain from the use of caffeine containing beverages during confinement in the clinical center
  • Blood donation or loss of significant amount of blood within 2 months prior to the first dosing
  • For women: Positive pregnancy test at screening or on Day -2; Pregnancy or trying to become pregnant; Breastfeeding
  • Any other condition that in the opinion of the Investigator would interfere with the evaluation of the results or constitute a health risk for the subject.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Placebo comparator
    Placebo (Study Part I)

    Hard gelatin capsules, oral administration, 5 or 6 capsules per day before breakfast with a glass of water

    Drug: Placebo

  • Experimental
    GFT505 300 mg (Study Part I)

    Hard gelatin capsules dosed at 60mg, oral administration, 5 capsules per day before breakfast with a glass of water

    Drug: GFT505

  • Experimental
    GFT505 360 mg (Study Part I)

    Hard gelatin capsules dosed at 60mg, oral administration, 6 capsules per day before breakfast with a glass of water

    Drug: GFT505

  • Placebo comparator
    Placebo (Study Part II)

    Hard gelatin capsules, oral administration, 4 to 6 capsules per day before breakfast with a glass of water

    Drug: Placebo

  • Experimental
    GFT505 120 mg (Study Part II)

    Hard gelatin capsules dosed at 60mg, oral administration, 2 capsules per day plus 2 to 4 capsules of placebo per day before breakfast with a glass of water

    Drug: GFT505

  • Experimental
    GFT505 xx mg (Study Part II)

    Supra-therapeutic dose: hard gelatin capsules dosed at 60mg, oral administration, 4 to 6 capsules per day before breakfast with a glass of water

    Drug: GFT505

  • Active comparator
    Moxifloxacin 400 mg (Study Part II)

    On days 1 to 13, 4 to 6 placebo capsules per day, then one 400 mg moxifloxacin tablet (Izilox®, Bayer Pharmaceuticals Corporation) administered orally on Day 14

    Drug: Moxifloxacin 400 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Safety parameters such as adverse event monitoring, vital signs, ECG, and clinical laboratory tests (Study Part I)

    To evaluate the safety and tolerability of two dose levels of GFT505 (300 and 360 mg), after multiple dose administration once daily for 14 days in male healthy subjects in order to determine the supra-therapeutic dose to be administered in Study Part II.

    Time frame: 14 days

  2. Effect on QTcF compared to placebo (Study Part II)

    To evaluate the impact on QTcF of two dose levels (one therapeutic and one supra-therapeutic according to ICH E14) of GFT505, after multiple dose administration once daily for 14 days in healthy male and female subjects compared to placebo and a positive control.

    Time frame: 14 days

Secondary outcomes

  1. Pharmacokinetic parameters including Cmax, Tmax, AUCt (Study Part I)

    To determine the PK parameters of GFT505 and GFT1007 after multiple dose administration once daily for 14 days in male subjects.

    Time frame: 14 days

  2. Safety parameters such as adverse event monitoring, vital signs, ECG, and clinical laboratory tests (Study Part II)

    To evaluate the safety and tolerability of GFT505 in healthy male and female subjects after multiple dose administration of a therapeutic dose and a supra-therapeutic dose

    Time frame: 14 days

  3. Effect on QTcB compared to placebo (Study Part II)

    To evaluate the impact on QTcB of two dose levels (one therapeutic and one supra-therapeutic according to ICH E14) of GFT505, after multiple dose administration once daily for 14 days in healthy male and female subjects compared to placebo and a positive control.

    Time frame: 14 days

07

Study locations

1 site
  • Eurofins Optimed
    Gières, 38610, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Dec 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2014
First posted
Mar 19, 2014
Start
Feb 2014
Primary completionActual
Dec 2014
CompletionActual
Feb 2015
Last update
Mar 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02091310
Lead sponsor
Genfit
Collaborators
Eurofins Optimed, CardiaBase, PhinC Development
Responsible party
Sponsor
First posted
Mar 19, 2014
Start date
Feb 2014
Primary completion
Dec 2014
Completion
Feb 2015
Last update
Mar 10, 2015

Study contacts

Rémy Hanf, PhD
study director · Genfit

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion